Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | KDM1A | O60341 | 3/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.47 |
| ▸ | SMOX | Q9NWM0 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.43 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17741702 | 0.82 | MAOA (0.60) | GAAGFERMAOAKDM1ARCOR1 | |
| SCHEMBL7397967 | 0.78 | GAA (0.62) | GAAKMT2AMEN1GFERMAPT | |
| SCHEMBL17741703 | 0.73 | MAOA (0.57) | MAOAKDM1ARCOR1SMOX | |
| SCHEMBL17742133 | 0.73 | MAOA (0.57) | GAAKMT2AMEN1GFERMAOA | |
| SCHEMBL19161005 | 0.73 | MAPT (0.47) | SMN1; SMN2GAAKMT2AMAPTTDP1 | |
| SCHEMBL16995668 | 0.73 | MAPT (0.49) | KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL14027208 | 0.72 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAMAPTTDP1ALDH1A1 | |
| SCHEMBL17742090 | 0.71 | MAOA (0.56) | MAOAKDM1ARCOR1SMOX | |
| SCHEMBL1513177 | 0.71 | SMN1; SMN2 (0.43) | SMN1; SMN2KMT2AMEN1MAPTTDP1 | |
| SCHEMBL8351640 | 0.70 | MCL1 (0.52) | SMN1; SMN2GAAKMT2AMEN1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509467-B2 | CGAS inhibiting triazolopyrimidone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230374014-A1 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4153593-A1 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| CN-115667265-A | CGAS-inhibiting triazolopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509467-B2 | CGAS inhibiting triazolopyrimidone derivatives | CGAS, STING1, IRF3 | SMN1; SMN2 3508/4885GAA 57/4885KMT2A 4465/4885 |
| US-20230374014-A1 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | CGAS, GLS2, GBA3 | SMN1; SMN2 3629/4885GAA 30/4885KMT2A 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.